American Society of Hematology

Fig. 1.

$Fig. 1. Treatment protocol for nonmyeloablative HCT. / Granulocyte colony-stimulating factor (G-CSF)–mobilized peripheral blood stem cells (PBSCs) were infused after TBI on day 0. One patient (FH14726) received fludarabine 30 mg/m2 ×3 intravenously on days −4, −3, and −2 before TBI/MMF/CSP. G-CSF: 16 μg per kg per day on days −4 to 0, aphereses on days −1, 0; TBI: 200 cGy (7 cGy/min) single fraction; HCT: PBSCs infused on day 0; CSP: 1.5 mg/kg intravenously twice daily on days −1 and 0, 6.25 mg/kg orally twice daily on days 1 to +35 (cohort 1), then taper to +56 (cohort 2); MMF: 15 mg/kg orally twice daily on days 0 to +27; DLI: no. 1 equals 107 CD3+ cells/kg, no. 2 equals 3.3 × 107 CD3+ cells/kg.$

Treatment protocol for nonmyeloablative HCT.

Granulocyte colony-stimulating factor (G-CSF)–mobilized peripheral blood stem cells (PBSCs) were infused after TBI on day 0. One patient (FH14726) received fludarabine 30 mg/m² ×3 intravenously on days −4, −3, and −2 before TBI/MMF/CSP. G-CSF: 16 μg per kg per day on days −4 to 0, aphereses on days −1, 0; TBI: 200 cGy (7 cGy/min) single fraction; HCT: PBSCs infused on day 0; CSP: 1.5 mg/kg intravenously twice daily on days −1 and 0, 6.25 mg/kg orally twice daily on days 1 to +35 (cohort 1), then taper to +56 (cohort 2); MMF: 15 mg/kg orally twice daily on days 0 to +27; DLI: no. 1 equals 10⁷ CD3⁺ cells/kg, no. 2 equals 3.3 × 10⁷ CD3⁺ cells/kg.

This Feature Is Available To Subscribers Only